Hosted on Acast. See acast.com/privacy for more information.

During the European Hematology Association (EHA) 2024 Hybrid Congress, the Lymphoma Hub was pleased to speak to Paolo Ghia, Vita-Salute San Raffaele, Milan, IT. We asked about the latest updates from the SEQUOIA trial of zanubrutinib + venetoclax in treatment-naïve patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). 

In this interview, Paolo Ghia shares data from Arm D of the phase III SEQUOIA (NCT03336333) study of patients with del(17p) and/or pathogenic TP53 mutation treated with zanubrutinib in combination with venetoclax. Ghia covers key preliminary outcomes, highlighting promising remission data and an increased depth of response measured over time. This interview concludes with a look at the future implications of these data, particularly on measurable residual disease-guided treatment cessation.

This educational resource is independently supported by BeiGene. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource. 

Hosted on Acast. See acast.com/privacy for more information.

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US. We asked for an update on the SYMPHONY 1 trial (NCT04224493).

First, Salles explains the rationale for using tazemetostat, an oral EZH2 inhibitor, with lenalidomide and rituximab in the phase Ib SYMPHONY 1 trial for patients with relapsed/refractory follicular lymphoma. This is followed by an overview of the study design and a review of the adverse effects and response rates. The results of this study have prompted the combination to be further investigated in a phase III trial. 

Hosted on Acast. See acast.com/privacy for more information.

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Chan Cheah, University of Western Australia, Perth, AU. We asked for an update on novel therapies in chronic lymphocytic leukemia (CLL).

Cheah reviews the abstracts that were presented at ASH on novel BTK inhibitors and Bcl-2 inhibitors for relapsed/refractory CLL. This includes an analysis of the potency, toxicity, and MRD response rates of the Bcl-2 inhibitor, BGB-11417, as well as the results of the phase I/II BRUIN study of the non-covalent BTK inhibitor, pirtobrutinib, in heavily pretreated patients with CLL and patients with Richter’s transformation.

Hosted on Acast. See acast.com/privacy for more information.

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Pere Barba, Hospital Universitari Vall d'Hebron, Barcelona, ES. We asked, What are the chimeric antigen receptor (CAR) T-cell therapies on the horizon for lymphoma?

Barba summarizes the progress made in the development of second generation CD19 CAR T-cell therapies, dual CAR T-cell therapies, allogeneic CAR T-cell platforms, alternatives to CD19 CAR T-cell therapies, and combining checkpoint inhibitors with conventional CAR T-cell therapies. 

Hosted on Acast. See acast.com/privacy for more information.

The Lymphoma Hub was pleased to speak with Francesc Bosch, Vall d’Hebron Barcelona Hospital Campus, Barcelona, ES. We asked, How do you choose among different BTK inhibitors for treating CLL?

Bosch opens by outlining common BTK inhibitors such as ibrutinib, acalabrutinib, and zanubrutinib, noting that comparable efficacy and activity rates can cause difficulty when determining the most appropriate treatment; however, safety profiles vary. Bosch goes on to suggest that other factors, such as patient comorbidities, may be more useful; for example, the varying cardiovascular toxicity of BTK inhibitors may be pertinent when treating patients with comorbid cardiovascular conditions.

Hosted on Acast. See acast.com/privacy for more information.

The Lymphoma Hub was pleased to speak with Astrid Pavlovsky, FUNDALEU, Buenos Aires, AR. We asked, What are the latest advances in basal PET/CT for Hodgkin and non-Hodgkin lymphoma?

Pavlovsky outlines the progress made in the use of interim positron emission tomography (PET) to guide therapeutic decisions in the last decade, but also notes its limitations, before discussing the latest improvements in basal imaging methods. Pavlovsky goes on to emphasize the prognostic importance of baseline metabolic tumor volume by PET/computerized tomography, especially when combined with interim PET and other parameters such as the International Prognostic Score.

Hosted on Acast. See acast.com/privacy for more information.

Hosted on Acast. See acast.com/privacy for more information.

During the ASCO2022 congress, the Lymphoma Hub was pleased to speak with Anita Kumar, Memorial Sloane Kettering Cancer Center, New York, US. We asked, What is on the horizon for the frontline treatment of mantle cell lymphoma (MCL)? 

Kumar begins by discussing the historic treatment options for patients with MCL before highlighting that, in the future, clinicians hope to utilize information on clinical and biological baseline features that patients present with, and incorporate novel targeted therapies and MRD assessments to further individualize treatment for MCL. Kumar describes how increased pathobiological understanding has led to developments in the relapsed/refractory setting; results of studies, such as SHINE, have explored this. Finally, Kumar discusses other therapeutic options and outlines adverse events and efficacy seen in the current OASIS phase III trial.

Hosted on Acast. See acast.com/privacy for more information.

During the 16th International Conference on Malignant Lymphoma (16-ICML), the Lymphoma Hub spoke with Laurie Sehn, The University of British Columbia, Vancouver, CA, and Grzegorz Nowakowski, Mayo Clinic, Rochester, US. We asked, Is frontline R-CHOP still the standard of care for DLBCL?

They begin by revisiting a debate from ICML centering on what the optimal upfront therapy is for DCLB, for Sehn R-CHOP remains the standard of care in most settings and Nowakowski suggests instances where other approaches might be preferred. They go on to discuss recent clinical studies and their impact on the current treatment landscape of DLBCL. Finally they explore how to integrate the results from clinical trials and highlight a promising future for DCLB treatment.

Hosted on Acast. See acast.com/privacy for more information.